AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

ClinicalTrials.gov ID: NCT06991114

Public ClinicalTrials.gov record NCT06991114. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 17, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases

Study identification

NCT ID: NCT06991114
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Artiva Biotherapeutics, Inc.; Industry
Enrollment: 90 participants

Conditions and interventions

Conditions

Interventions

Allogeneic NK Cells Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 8, 2025
Primary completion: Dec 31, 2027
Completion: Dec 31, 2028
Last update posted: Dec 23, 2025

2025 – 2029

United States locations

U.S. sites: 16
U.S. states: 9
U.S. cities: 15

Facility	City	State	ZIP	Site status
Artiva Investigational Site Tuscaloosa	Tuscaloosa	Alabama	35406	Recruiting
Artiva Investigational Site Phoenix	Phoenix	Arizona	85037	Recruiting
Artiva Investigational Site Covina	Covina	California	91723	Recruiting
Artiva Investigational Site Los Alamitos	Los Alamitos	California	90720	Recruiting
Artiva Investigational Site Aventura	Aventura	Florida	33180	Recruiting
Artiva Investigational Site Jupiter	Jupiter	Florida	33458	Recruiting
Artiva Investigational Site Plantation	Plantation	Florida	33324	Recruiting
Artiva Investigational Site Willowbrook	Willowbrook	Illinois	60527	Recruiting
Artiva Investigational Site Iowa	Iowa City	Iowa	52242	Recruiting
Artiva Investigational Site Charlotte	Charlotte	North Carolina	28207	Recruiting
Artiva Investigational Site Charlotte	Charlotte	North Carolina	28625	Recruiting
Artiva Investigational Site Hixson	Hixson	Tennessee	37343	Recruiting
Artiva Investigational Site Arlington	Arlington	Texas	76012	Recruiting
Artiva Investigational Site Katy	Katy	Texas	77494	Recruiting
Artiva Investigational Site Mesquite	Mesquite	Texas	75150	Recruiting
Artiva Investigational Site Woodland	Woodland	Texas	77382	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06991114, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 23, 2025 · Synced May 17, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06991114 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →